MYGN Loss Alert: Hagens Berman Reminds Myriad Genetics (MYGN) Investors of Ongoing Investigation for Possible Disclosure Violations

Editorial & Advertiser Disclosure Global Banking And Finance Review is an independent publisher which offers News, information, Analysis, Opinion, Press Releases, Reviews, Research reports covering various economies, industries, products, services and companies. The content available on globalbankingandfinance.com is sourced by a mixture of different methods which is not limited to content produced and supplied by various staff writers, journalists, freelancers, individuals, organizations, companies, PR agencies etc. The information available on this website is purely for educational and informational purposes only. We cannot guarantee the accuracy or applicability of any of the information provided at globalbankingandfinance.com with respect to your individual or personal circumstances. Please seek professional advice from a qualified professional before making any financial decisions. Globalbankingandfinance.com also links to various third party websites and we cannot guarantee the accuracy or applicability of the information provided by third party websites.
Links from various articles on our site to third party websites are a mixture of non-sponsored links and sponsored links. Only a very small fraction of the links which point to external websites are affiliate links. Some of the links which you may click on our website may link to various products and services from our partners who may compensate us if you buy a service or product or fill a form or install an app. This will not incur additional cost to you. For avoidance of any doubts and to make it easier, you may consider any links to external websites as sponsored links. Please note that some of the services or products which we talk about carry a high level of risk and may not be suitable for everyone. These may be complex services or products and we request the readers to consider this purely from an educational standpoint. The information provided on this website is general in nature. Global Banking & Finance Review expressly disclaims any liability without any limitation which may arise directly or indirectly from the use of such information.

SAN FRANCISCO, Sept. 17, 2019 — Hagens Berman reminds investors in Myriad Genetics, Inc. (NASDAQ: MYGN) of the firm’s investigation of possible disclosure violations.

RELEVANT HOLDING PERIOD: Before Aug. 14, 2019 Email: [email protected] Visit: www.hbsslaw.com/investor-fraud/MYGN Call: Reed Kathrein, who is leading the firm’s investigation: 510-725-3000

Myriad Investigation:

The firm’s investigation concerns the accuracy of Myriad’s statements regarding its GeneSight® Psychotropic test, a kit intended to analyze how a patient’s genes may affect their response to certain drugs.  The Company has repeatedly promoted the quality and attributes of this new product. 

But on Aug. 13, 2019, Myriad shocked investors when it disclosed that the FDA had demanded changes to GeneSight®.  Although the Company claimed to have submitted a proposed solution, Myriad admitted that it did not know if regulators would accept the changes.  Myriad also refused to discuss how increased regulatory scrutiny may impact sales of the test.  This news drove the price of Myriad shares down 42%.

If you invested in Myriad before Aug. 14, 2019 and suffered significant losses contact Hagens Berman immediately to discuss your options.

“We’re focused on investors’ losses, and whether issues with GeneSight® should have been disclosed earlier,” said Hagens Berman partner Reed Kathrein.

Whistleblowers: Persons with non-public information regarding Myriad should consider their options to help in the investigation or take advantage of the SEC Whistleblower program.  Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.  For more information, call Reed Kathrein at 510-725-3000 or email [email protected].

About Hagens Berman Hagens Berman is a national law with nine offices in eight cities around the country and eighty attorneys.  The firm represents investors, whistleblowers, workers and consumers in complex litigation.  More about the firm and its successes is located at hbsslaw.com.  For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.

Contact: Reed Kathrein, 510-725-3000

 

Primary Logo